Short answer
HARROW, INC. (HROW) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $44M (down 7.6% year over year) with net income of −$28M.
Q1 2026 key financials · XBRL
- Revenue
- $44M
- −7.6% YoY
- Net income
- −$28M
- −55.2% YoY
- Operating margin
- -50.0%
- Gross margin
- 61.2%
- EPS (diluted)
- −$0.74
- −48.0% YoY
Source: XBRL data from the HARROW, INC. (HROW) Q1 2026 10-Q on SEC EDGAR. USD.
HARROW, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Reimbursement risk updated: CMS GLOBE and GUARD proposals could impose international-benchmark rebates on ophthalmic products
- Pricing exposure: limited control over non-U.S. prices may increase vulnerability to most-favored-nation benchmarks
- Compliance risk: disputed rebate and chargeback claims could require adverse revenue adjustments
- Near-term market risk: prior authorization, formulary restrictions, and patient cost sharing may reduce product access
- Financial risk: inaccurate gross-to-net estimates could reduce revenues, margins, cash flows, and financial condition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HARROW, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.